IKT vs. ORGO, GHRS, ALMS, QURE, BCYC, KURA, URGN, MGTX, IMTX, and ARVN
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Organogenesis (ORGO), GH Research (GHRS), Alumis (ALMS), uniQure (QURE), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), UroGen Pharma (URGN), MeiraGTx (MGTX), Immatics (IMTX), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.
Inhibikase Therapeutics vs.
Inhibikase Therapeutics (NYSE:IKT) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
Organogenesis received 88 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Inhibikase Therapeutics an outperform vote while only 65.99% of users gave Organogenesis an outperform vote.
3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 4.6% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 36.9% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Inhibikase Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Inhibikase Therapeutics' return on equity.
Organogenesis has higher revenue and earnings than Inhibikase Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.
Inhibikase Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.
In the previous week, Organogenesis had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 5 mentions for Organogenesis and 4 mentions for Inhibikase Therapeutics. Organogenesis' average media sentiment score of 1.02 beat Inhibikase Therapeutics' score of 0.33 indicating that Organogenesis is being referred to more favorably in the news media.
Inhibikase Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 242.11%. Organogenesis has a consensus price target of $5.50, indicating a potential upside of 27.31%. Given Inhibikase Therapeutics' higher probable upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than Organogenesis.
Summary
Organogenesis beats Inhibikase Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:IKT) was last updated on 4/16/2025 by MarketBeat.com Staff
Buy IKT Stock Free IKT Stock Alerts